The BD Max molecular testing system will enable laboratories to run both laboratory- and BD-developed assays and offer testing services that elevate the standards of care at their institutions.
Tom Polen, president of diagnostic systems at BD Diagnostics, said: 'In a world with ever-evolving pathogens, laboratories need to provide clinicians with fast, accurate and actionable diagnostic information that will save patient lives.
'The new, completely open BD Max system empowers laboratories to automate their unique internally developed molecular assays while accessing assays from BD and our leading assay development partners,' he added.
BD Max is claimed to be the first fully automated, open, bench-top molecular testing workstation able to perform both IVD/CE and laboratory-developed tests.
The system gives clinical laboratory professionals the ability to help their institutions respond to emerging threats, such as new strains of deadly drug-resistant bacteria or respiratory illnesses.
The BD Max system's content-rich menu, open capability, full automation and standardised workflow will enable laboratories to consolidate and standardise a range of molecular tests to build programs that meet both their current and future clinical needs, according to the company.
The system will enable European laboratories to run their current laboratory-developed assays as well as to develop new ones.
